NRIX
HOLD / NEUTRALMeanRevComposite
59.50
Technical
66.10
Fundamental
57.40
Rank
—
Price
26.02
Hurst
0.35
As of
Oct 22, 2026
Daily
Nurix Therapeutics, Inc.
HealthcareBiotechnologyNurix Therapeutics is a biopharmaceutical company developing small molecule and antibody treatments for cancer, inflammatory diseases, and other conditions. The company's pipeline includes several drug candidates in early-stage clinical testing, such as BTK degraders for blood cancers and autoimmune disorders, a CBL-B inhibitor for immunotherapy applications, and an IRAK4 degrader for rheumatoid arthritis. Nurix has partnerships with Gilead Sciences, Sanofi, and Pfizer for the development and commercialization of its therapeutic candidates.
Market cap
$2.9B
P/E (trailing)
11.03
P/E (forward)
-21.01
PEG ratio
—
Dividend yield
0.00%
Beta
1.82
52w range
11.67 – 28.23
Return on equity
+43.99%
Profit margin
+42.01%
Revenue growth
+8426.30%
Earnings growth
—
Price history
1Y: 26.80 (+107.1%) · range 12.17–27.79
Cycle position
76/ 100 cycle scoreEXIT ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 4 · NOT READY · exit proximity 23
Conviction
25/ 100 · maturity 100%
VScore.4020
Buildup.2035
EMA entry setup.254
Fundamentals.1557
Volume profile
POC
23.61
Price vs POC
+13.5%
Overhead supply
5%
Runway
open sky
Value area 17.88–28.23 · 5% of 120d volume overhead · clean runway
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.400 | Oct 30, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -2.61% | -1.96% | 2/20d |
| 40d | -2.61% | -1.96% | 2/40d |